Document Detail


Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.
MedLine Citation:
PMID:  21040499     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background:  Interventions that preserve or increase β-cell mass may also prevent Type 2 diabetes. Rosiglitazone alone, as well as in combination with metformin, prevents diabetes in people with high, yet non-diabetic glucose levels. These effects may be mediated through changes in β-cell mass. In the present study, the effect of combining rosiglitazone with metformin and/or insulin on β-cell mass and glucose levels was examined in a rat model of Type 2 diabetes. Methods:  Diabetes-prone pups were randomized to receive rosiglitazone alone or in combination with metformin and/or insulin starting at 4 weeks of age. β-Cell mass and glucose homeostasis were examined in adulthood. Results:  Rosiglitazone treatment reduced insulin resistance and partially restored β-cell mass in animals with reduced β-cell mass at birth. The addition of metformin to rosiglitazone decreased insulin resistance and reduced weight gain, but had no additional effect on β-cell mass. Conversely, the addition of insulin had no additional effect on these outcomes. Although the combination of rosiglitazone and metformin did not affect β-cell mass at 26 weeks of age, it did result in reduced body weight and insulin resistance. Conclusion:  The results of the present study suggest that the addition of metformin to rosiglitazone improves the metabolic profile through an effect on insulin resistance and not β-cell mass.
Authors:
Alison C Holloway; Bart P Hettinga; Hertzel C Gerstein
Related Documents :
20880339 - In support of an early polypharmacy approach to the treatment of type 2 diabetes.
15975669 - Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes.
20307399 - Glucose supply and insulin demand dynamics of antidiabetic agents.
9737829 - A retrospective chart review of uncontrolled use of metformin as an add-on therapy in t...
8864639 - Clinical profile of the novel sulphonylurea glimepiride.
8112499 - Metformin--an update.
8432409 - Cd8+ t-cells are required for adoptive transfer of the bb rat diabetic syndrome.
20922819 - Evolution and predictors of morphological and functional arterial changes in the course...
3131049 - Anomeric specificity of d-glucose metabolism in human erythrocytes.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of diabetes     Volume:  3     ISSN:  1753-0407     ISO Abbreviation:  J Diabetes     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101504326     Medline TA:  J Diabetes     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  74-81     Citation Subset:  IM    
Copyright Information:
© 2011 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.
Affiliation:
Reproductive Biology Division, Department of Obstetrics and Gynecology, McMaster University Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tissue specificity on insulin action and resistance: past to recent mechanisms.
Next Document:  Can dietary fructans lower serum glucose?